Advertisement
ABBV vs BIIB
Which Stock Would AI Choose? AbbVie Inc. (ABBV) vs. Biogen Inc. (BIIB) Stock Comparison
Key Takeaways
- ABBV has outperformed year-to-date with an 11.61% return compared to BIIB's 4.77%, reflecting greater stability in recent market activity.
- BIIB delivers superior one-year performance at 54.28% versus ABBV's 13.76%, driven by momentum in neurology pipeline developments.
- ABBV's market capitalization stands at $351 billion, dwarfing BIIB's $27 billion, highlighting scale differences in the biopharmaceutical sector.
- BIIB trades at a lower price-to-earnings (P/E) ratio of 21x compared to ABBV's 84x, suggesting relatively attractive valuation.
- Recent analyst upgrades bolster BIIB sentiment, while ABBV navigates a U.S. FDA Complete Response Letter (CRL) on its trenibotulinumtoxinE application.
- Both stocks gear up for first-quarter 2026 earnings releases on April 29, potentially influencing short-term relative performance.
Introduction
ABBV and BIIB represent key players in the biopharmaceutical industry, with overlapping exposure to immunology and neuroscience therapeutics. This stock comparison analyzes their business models, recent performance, and market positioning amid evolving sector dynamics like patent transitions and pipeline advancements. Investors seeking diversified large-cap stability may eye ABBV, while those pursuing higher-growth biotech opportunities with neurology focus might consider BIIB. Traders monitoring relative performance and upcoming catalysts will find insights into momentum shifts and risk-reward trade-offs in the current market environment.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a leading biopharmaceutical company specializing in immunology, oncology, neuroscience, and aesthetics. Its portfolio features blockbuster drugs like Skyrizi and Rinvoq, which have offset declines from the Humira patent expiration. In recent market activity, ABBV shares traded around $198.71, within a 52-week range of $176.57 to $244.81. Year-to-date gains reached 11.61%, supported by a robust dividend yield of 3.48% and strong free cash flow generation. Sentiment faced pressure in recent weeks following a U.S. FDA Complete Response Letter on its trenibotulinumtoxinE (TrenibotE) biologics license application due to manufacturing issues, though no safety concerns were raised. Analysts maintain a positive outlook with an average price target of $249, ahead of first-quarter earnings.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) focuses on neurology therapeutics, including multiple sclerosis (MS) treatments like Tecfidera and Vumerity, alongside emerging assets in Alzheimer's and rare diseases such as Leqembi and Zurzuvae. Shares recently closed near $184.38, spanning a 52-week range from $115.25 to $202.41. The stock delivered a one-year return of 54.28%, though year-to-date performance stood at 4.77%. Recent weeks brought optimism via UBS's upgrade to Buy with a $225 price target, citing pipeline catalysts into 2027, including collaborations like felzartamab for immune diseases in China. Declines in legacy MS franchise sales pose challenges, but new launches and R&D momentum have lifted sentiment. Average analyst targets reach $212, with first-quarter earnings on deck.
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top-performing AI trading bots from a library of 351 bots that analyze and trade thousands of tickers across diverse strategies, timeframes, and sectors. These bots excel in current market conditions, showcasing annualized returns ranging from 15% to over 167%, win rates between 48% and 88%, and profit factors up to 11.7. Examples target high-momentum areas like semiconductors (NVDA, AMD), leveraged ETFs, gold miners, aerospace, and finance, with trade durations from hours to months and built-in risk management. Selected for superior real-time signals and adaptability, they help traders navigate volatility. Explore Trending AI Robots to identify bots matching your trading style and market outlook.
Head-to-Head Comparison
ABBV and BIIB diverge in scale and focus: ABBV's diversified model spans multiple therapeutic areas with reliable revenue from immunology leaders, contrasting BIIB's neurology-centric biotech approach amid MS sales erosion. Growth drivers for ABBV include Skyrizi/Rinvoq expansion, while BIIB banks on Alzheimer's approvals and rare disease deals. Recent momentum favors BIIB with analyst upgrades versus ABBV's regulatory hiccup. Risk factors highlight ABBV's patent cliffs and high leverage against BIIB's pipeline dependency. Market sentiment tilts toward BIIB for upside potential, though ABBV offers defensive positioning in volatile biotech exposure.
Tickeron AI Verdict
Tickeron's AI currently favors BIIB over ABBV, based on stronger one-year trend consistency, recent analyst momentum from pipeline catalysts, and a more attractive valuation amid upcoming earnings. While ABBV provides scale and dividend stability, BIIB's relative positioning suggests higher probability of near-term outperformance in the biotech sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and BIIB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileBIIB’s FA Score has 1 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- BIIB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while BIIB’s TA Score has 3 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 4 bearish.
- BIIB’s TA Score: 3 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а -0.08% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +1.79% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.90%. For the same industry, the average monthly price growth was +7.32%, and the average quarterly price growth was +5.17%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
BIIB is expected to report earnings on Jul 16, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.90% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | BIIB | ABBV / BIIB | |
| Capitalization | 397B | 29.5B | 1,346% |
| EBITDA | 16.9B | 2.7B | 626% |
| Gain YTD | -0.014 | 13.620 | -0% |
| P/E Ratio | 110.18 | 21.50 | 512% |
| Revenue | 62.8B | 9.94B | 632% |
| Total Cash | 9.39B | 4.28B | 219% |
| Total Debt | 72.9B | 6.56B | 1,111% |
ABBV | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 11 | 100 | |
SMR RATING 1..100 | 1 | 79 | |
PRICE GROWTH RATING 1..100 | 35 | 46 | |
P/E GROWTH RATING 1..100 | 25 | 16 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (10) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (83) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.
ABBV's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (79) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.
ABBV's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as BIIB (46) in the Biotechnology industry. This means that ABBV’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's P/E Growth Rating (16) in the Biotechnology industry is in the same range as ABBV (25) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to ABBV’s over the last 12 months.
| ABBV | BIIB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 37% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 43% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 57% |
| MACD ODDS (%) | N/A | 2 days ago 54% |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 58% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 59% |
| Advances ODDS (%) | 8 days ago 57% | 9 days ago 56% |
| Declines ODDS (%) | 2 days ago 48% | 5 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 33% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 65% | 2 days ago 65% |
Advertisement